Lamisil cream

Ülke: Ermenistan

Dil: İngilizce

Kaynak: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Aktif bileşen:

terbinafine (terbinafine hydrochloride)

Mevcut itibaren:

GlaxoSmithKline Consumer Healthcare S.A.

ATC kodu:

D01AE15

INN (International Adı):

terbinafine (terbinafine hydrochloride)

Doz:

10mg/g

Farmasötik formu:

cream

Paketteki üniteler:

15g aluminium tube, 15g laminated tube

Reçete türü:

OTC

Yetkilendirme durumu:

Registered

Yetkilendirme tarihi:

2020-01-09

Ürün özellikleri

Global Drug Regulatory Affairs
LAMISIL1% CREAM
Terbinafine
SUMMARY OF PRODUCT CHARACTERISTICS
Property of GSK Consumer Healthcare S.A.
Confidential
May not be used, divulged, published or otherwise disclosed
without the consent of GSK Consumer Healthcare S.A.
CONTENTS
1.
NAME OF THE MEDICINAL PRODUCT
...............................................................................
3
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
..................................................... 3
3.
PHARMACEUTICAL FORM
....................................................................................................
3
4.
CLINICAL PARTICULARS
......................................................................................................
3
4.1.
Therapeutic indications
..................................................................................................
3
4.2.
Posology and method of administration
.........................................................................
3
4.3.
Contra-indications
..........................................................................................................
4
4.4.
Special warnings and precautions for use
......................................................................
4
4.5.
Interactions with other medicinal products and other forms of
interaction ................... 4
4.6.
Pregnancy and lactation
.................................................................................................
4
4.7.
Effects on ability to drive and use machines
................................................................. 5
4.8.
Undesirable effects
.........................................................................................................
5
4.9.
Overdose
........................................................................................................................
5
5.
PHARMACOLOGICAL PROPERTIES
....................................................................................
6
5.1.
Pharmacodynamic properties
.........................................